StockData
Climb Bio, Inc. logo

Climb Bio, Inc. (CLYM) stock

CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$9.30−0.48 (-4.91%)

Close on Nov 18, 2026Market cap $534.16MP/E –Yield –

Climb Bio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

No revenue figures for Climb Bio

Climb Bio has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Climb Bio figures

See a number that looks wrong?